DFTX

Definium Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for rare genetic diseases caused by protein misfolding. The company's lead programs target cystic fibrosis and alpha-1 antitrypsin deficiency using small molecule chaperone therapeutics designed to correct the folding and trafficking of mutant proteins. Definium's platform technology aims to restore protein function by stabilizing cellular proteins in their proper three-dimensional structure. The company advances drug candidates through preclinical and clinical development with the goal of addressing significant unmet medical needs in genetic disorders.